AR084706A1 - Derivados sustituidos de imidazoquinolinas como inhibidores de quinasa y proceso para su preparacion - Google Patents
Derivados sustituidos de imidazoquinolinas como inhibidores de quinasa y proceso para su preparacionInfo
- Publication number
- AR084706A1 AR084706A1 ARP110102555A ARP110102555A AR084706A1 AR 084706 A1 AR084706 A1 AR 084706A1 AR P110102555 A ARP110102555 A AR P110102555A AR P110102555 A ARP110102555 A AR P110102555A AR 084706 A1 AR084706 A1 AR 084706A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- heterocyclyl
- heteroaryl
- aryl
- conrxry
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 8
- 125000000623 heterocyclic group Chemical group 0.000 abstract 8
- 125000000217 alkyl group Chemical group 0.000 abstract 7
- 125000002877 alkyl aryl group Chemical group 0.000 abstract 6
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 6
- 125000005213 alkyl heteroaryl group Chemical group 0.000 abstract 5
- -1 alkylheterocyclyl Chemical group 0.000 abstract 5
- 125000003118 aryl group Chemical group 0.000 abstract 5
- 125000003342 alkenyl group Chemical group 0.000 abstract 4
- 125000000304 alkynyl group Chemical group 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Reivindicación 1: Un compuesto de la fórmula (1) en donde, R1 se selecciona de -alquilo C1-8, -alquenilo C2-8, -alquinilo C2-8, -cicloalquilo C3-10, -arilo C6-14, heterociclilo, heteroarilo, alquilarilo, alquilheteroarilo, alquilheterociclilo, -CONRxRy y -CORx, en donde cada uno de alquilo, alquenilo, alquinilo, cicloalquilo, arilo, heterociclilo, heteroarilo, alquilarilo, alquilheteroarilo y alquilheterociclilo se sustituye opcionalmente con uno o más de Ra; R2 se selecciona de nitro, -CN, -CONRxRy, -COORx, -S(=O)mRx, -S(=O)nNRxRy, -alquilo C1-6 o -alcoxi C1-8, en donde -alquilo C1-6 se sustituye opcionalmente con -CN y -NRxRy; R3 es hidrógeno, -CORx, S(=O)mRx, -CONRxRy y -alquilo C1-8, en donde -alquilo C1-8 se sustituye opcionalmente con uno o más grupos seleccionados de -CN, -CONRxRy, -CORx, -COORx, -NRxRy y -S(=O)mRx; R4, R5 y R7 se seleccionan de H, nitro, halógeno, -CN, -ORx, -CONRxRy, -NRxCORy, -NRxSO2Ry, -NRxCONRxRy, -CORx, -alquilo C1-8, -arilo C6-14, heterociclilo o heteroarilo, en donde cada uno de alquilo, arilo, heterociclilo, y heteroarilo se sustituye opcionalmente con uno o más de Ra; R6 se selecciona de H, halógeno, -NRxRy, -NRxCORy, -ORx, -SRx y R1; Ra en cada incidencia se selecciona de halógeno, nitro, -CN, ORx, S(=O)mRx, -S(=O)nNRxRy, -NRxRy, NRxCORy, NRxCOORy, -NRxSORy, -NRxSO2Ry, -NRxCONRxRy, -CORx, -COORx, -CONRxRy, -alquilo C1-8, -alquenilo C2-8, -alquinilo C2-8, -arilo C6-14, alquilarilo, heterociclilo, alquilheterociclilo, heteroarilo o alquilheteroarilo, en donde cada uno de alquilo, alquenilo, alquinilo, arilo, alquilarilo, heterociclilo, alquilheterociclilo, heteroarilo y alquilheteroarilarilo se sustituye opcionalmente con uno o más de Rb; en donde Rx y Ry en cada incidencia se seleccionan independientemente de H, -alquilo C1-8, -alquenilo C2-8, -alquinilo C2-8, -cicloalquilo C3-10, alquilcicloalquilo, -arilo C6-14, alquilarilo, heterociclilo, alquilheterociclilo, heteroarilo o alquilheteroarilo, en donde cada uno de alquilo, alquenilo, alquinilo, cicloalquilo, alquilcicloalquilo, arilo, alquilarilo, heterociclilo, alquilheterociclilo, heteroarilo y alquilheteroarilo se sustituyen opcionalmente con Rb; Rb en cada incidencia se selecciona de halógeno, nitro, -CN, hidroxi, alcoxi, -COOH, -NH2 y -alquilo C1-8; m es 0 o un entero de 1 a 2; n es un entero de 1 a 2; o sales farmacéuticamente aceptables, estereoisómeros, tautómeros y óxidos-N de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36492710P | 2010-07-16 | 2010-07-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR084706A1 true AR084706A1 (es) | 2013-06-05 |
Family
ID=44509505
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110102555A AR084706A1 (es) | 2010-07-16 | 2011-07-15 | Derivados sustituidos de imidazoquinolinas como inhibidores de quinasa y proceso para su preparacion |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9062046B2 (es) |
| EP (1) | EP2593450A1 (es) |
| JP (1) | JP5750158B2 (es) |
| KR (1) | KR20130043198A (es) |
| CN (1) | CN103108873A (es) |
| AR (1) | AR084706A1 (es) |
| AU (1) | AU2011277935B2 (es) |
| BR (1) | BR112013001088A2 (es) |
| CA (1) | CA2805608A1 (es) |
| MX (1) | MX2013000617A (es) |
| NZ (1) | NZ607060A (es) |
| RU (1) | RU2013106427A (es) |
| TW (1) | TW201204725A (es) |
| WO (1) | WO2012007926A1 (es) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014141118A1 (en) | 2013-03-14 | 2014-09-18 | Piramal Enterprises Limited | Imidazo[4,5-c]quinoline derivatives and uses thereof |
| WO2014177915A1 (en) | 2013-05-01 | 2014-11-06 | Piramal Enterprises Limited | Cancer combination therapy using imidazo[4,5-c]quinoline derivatives |
| US9227969B2 (en) | 2013-08-14 | 2016-01-05 | Novartis Ag | Compounds and compositions as inhibitors of MEK |
| WO2015049629A1 (en) * | 2013-10-01 | 2015-04-09 | Piramal Enterprises Limited | Imidazoquinoline compounds as bromodomain inhibitors |
| AU2014348657A1 (en) | 2013-11-13 | 2016-05-19 | Novartis Ag | mTOR inhibitors for enhancing the immune response |
| ES2918501T3 (es) | 2013-12-19 | 2022-07-18 | Novartis Ag | Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos |
| EP3087101B1 (en) | 2013-12-20 | 2024-06-05 | Novartis AG | Regulatable chimeric antigen receptor |
| US20170335281A1 (en) | 2014-03-15 | 2017-11-23 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
| WO2015145369A1 (en) * | 2014-03-27 | 2015-10-01 | Piramal Enterprises Limited | Process for the preparation of substituted imidazo[4,5-c]quinoline compounds, intermediates and polymorphs thereof |
| AU2015244039B2 (en) | 2014-04-07 | 2021-10-21 | Novartis Ag | Treatment of cancer using anti-CD19 chimeric antigen receptor |
| JP2017528433A (ja) | 2014-07-21 | 2017-09-28 | ノバルティス アーゲー | 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ |
| TWI719942B (zh) | 2014-07-21 | 2021-03-01 | 瑞士商諾華公司 | 使用ｃｄ３３嵌合抗原受體治療癌症 |
| US11542488B2 (en) | 2014-07-21 | 2023-01-03 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
| WO2016012982A1 (en) * | 2014-07-25 | 2016-01-28 | Piramal Enterprises Limited | Combination therapy for the treatment of resistant breast cancer |
| EP4205749A1 (en) | 2014-07-31 | 2023-07-05 | Novartis AG | Subset-optimized chimeric antigen receptor-containing cells |
| AU2015301460B2 (en) | 2014-08-14 | 2021-04-08 | Novartis Ag | Treatment of cancer using GFR alpha-4 chimeric antigen receptor |
| MX2017002205A (es) | 2014-08-19 | 2017-08-21 | Novartis Ag | Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer. |
| JP6839074B2 (ja) | 2014-09-17 | 2021-03-03 | ノバルティス アーゲー | 養子免疫療法のためのキメラ受容体での細胞毒性細胞のターゲティング |
| KR20170068504A (ko) | 2014-10-08 | 2017-06-19 | 노파르티스 아게 | 키메라 항원 수용체 요법에 대한 치료 반응성을 예측하는 바이오마커 및 그의 용도 |
| WO2016141296A1 (en) * | 2015-03-04 | 2016-09-09 | Dana-Farber Caner Institute, Inc. | Tricyclic kinase inhibitors of melk and methods of use |
| ES2876974T3 (es) | 2015-04-07 | 2021-11-15 | Novartis Ag | Combinación de terapia con receptor de antígeno quimérico y derivados de amino pirimidina |
| AU2016249005B2 (en) | 2015-04-17 | 2022-06-16 | Novartis Ag | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
| EP3286211A1 (en) | 2015-04-23 | 2018-02-28 | Novartis AG | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
| CN114805352B (zh) * | 2015-07-11 | 2023-09-15 | 南京爱德程医药科技有限公司 | 作为pi3k/mtor抑制剂的吡咯并吡啶取代的稠合喹啉化合物 |
| EP3487878A4 (en) | 2016-07-20 | 2020-03-25 | University of Utah Research Foundation | CD229-CAR-T CELLS AND METHOD FOR USE THEREOF |
| BR112019006781A2 (pt) | 2016-10-07 | 2019-07-30 | Novartis Ag | receptores de antígeno quiméricos para o tratamento de câncer |
| EP3615055A1 (en) | 2017-04-28 | 2020-03-04 | Novartis AG | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| SG11202005719UA (en) * | 2017-12-20 | 2020-07-29 | Angex Pharmaceutical Inc | Carbamate and urea compounds as multikinase inhibitors |
| US10596165B2 (en) | 2018-02-12 | 2020-03-24 | resTORbio, Inc. | Combination therapies |
| WO2019210153A1 (en) | 2018-04-27 | 2019-10-31 | Novartis Ag | Car t cell therapies with enhanced efficacy |
| EP3788369A1 (en) | 2018-05-01 | 2021-03-10 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
| EP3790878A1 (en) * | 2018-05-11 | 2021-03-17 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Quinoline compounds and their preparation and use as antimalarial agents |
| WO2019241789A1 (en) | 2018-06-15 | 2019-12-19 | Navitor Pharmaceuticals, Inc. | Rapamycin analogs and uses thereof |
| AU2020337958A1 (en) | 2019-08-28 | 2022-03-17 | Horizon Therapeutics Ireland Dac | Methods for the treatment of thyroid eye disease |
| AU2020397938A1 (en) | 2019-12-05 | 2022-06-23 | Janssen Pharmaceutica Nv | Rapamycin analogs and uses thereof |
| WO2021150613A1 (en) | 2020-01-20 | 2021-07-29 | Incyte Corporation | Spiro compounds as inhibitors of kras |
| US11739102B2 (en) | 2020-05-13 | 2023-08-29 | Incyte Corporation | Fused pyrimidine compounds as KRAS inhibitors |
| US11999752B2 (en) | 2020-08-28 | 2024-06-04 | Incyte Corporation | Vinyl imidazole compounds as inhibitors of KRAS |
| US11767320B2 (en) | 2020-10-02 | 2023-09-26 | Incyte Corporation | Bicyclic dione compounds as inhibitors of KRAS |
| EP3992191A1 (en) | 2020-11-03 | 2022-05-04 | Deutsches Krebsforschungszentrum | Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors |
| WO2022204112A1 (en) | 2021-03-22 | 2022-09-29 | Incyte Corporation | Imidazole and triazole kras inhibitors |
| MX2024000357A (es) | 2021-07-07 | 2024-02-12 | Incyte Corp | Compuestos triciclicos como inhibidores de homologo de oncogen viral de sarcoma de rata kirsten (kras). |
| WO2023287896A1 (en) | 2021-07-14 | 2023-01-19 | Incyte Corporation | Tricyclic compounds as inhibitors of kras |
| US12441742B2 (en) | 2021-08-31 | 2025-10-14 | Incyte Corporation | Naphthyridine compounds as inhibitors of KRAS |
| WO2023049697A1 (en) | 2021-09-21 | 2023-03-30 | Incyte Corporation | Hetero-tricyclic compounds as inhibitors of kras |
| CA3234375A1 (en) | 2021-10-01 | 2023-04-06 | Incyte Corporation | Pyrazoloquinoline kras inhibitors |
| CA3235146A1 (en) | 2021-10-14 | 2023-04-20 | Incyte Corporation | Quinoline compounds as inhibitors of kras |
| AU2024287547A1 (en) | 2023-07-07 | 2026-01-22 | Viridian Therapeutics, Inc. | Methods of treating chronic thyroid eye disease |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5011828A (en) * | 1985-11-15 | 1991-04-30 | Michael Goodman | Immunostimulating guanine derivatives, compositions and methods |
| JP4782564B2 (ja) * | 2002-07-10 | 2011-09-28 | メルク セローノ ソシエテ アノニム | アゾリジノン−ビニル縮合−ベンゼン誘導体 |
| ES2328146T3 (es) * | 2003-07-28 | 2009-11-10 | Merck Serono Sa | 2-imino-4-(tio)oxo-5-policiclovinilazolinas para su uso como inhibidores de p13 quinasas. |
| AR046845A1 (es) * | 2003-11-21 | 2005-12-28 | Novartis Ag | Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas |
| PT1687305E (pt) * | 2003-11-21 | 2008-10-17 | Novartis Ag | Derivados de 1h-imidazoquinolina como inibidores de proteína quinase |
| DE102004019492A1 (de) * | 2004-04-22 | 2005-11-10 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| KR20070027584A (ko) * | 2004-06-17 | 2007-03-09 | 와이어쓰 | 고나도트로핀 방출 호르몬 수용체 길항제 |
| WO2006029115A2 (en) | 2004-09-02 | 2006-03-16 | 3M Innovative Properties Company | 2-amino 1h imidazo ring systems and methods |
| KR20070100686A (ko) * | 2004-09-07 | 2007-10-11 | 오르펀 메디칼, 인크. | 개선된 ｇｈｂ 조성물 |
| GB0510390D0 (en) * | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| AR056097A1 (es) * | 2005-09-29 | 2007-09-19 | Wyeth Corp | Derivados de propilamina sustituida y metodos para su utilizacion |
| WO2007075468A1 (en) * | 2005-12-16 | 2007-07-05 | Coley Pharmaceutical Group, Inc. | Substituted imidazoquinolines, imidazonaphthyridines, and imidazopyridines, compositions, and methods |
| JP2010537998A (ja) * | 2007-08-27 | 2010-12-09 | ワイス・エルエルシー | イミダゾピリジン類似体、およびＷｎｔ−βカテニン細胞メッセージ伝達系のアゴニストとしてのその使用 |
-
2011
- 2011-07-15 MX MX2013000617A patent/MX2013000617A/es not_active Application Discontinuation
- 2011-07-15 JP JP2013520262A patent/JP5750158B2/ja not_active Expired - Fee Related
- 2011-07-15 RU RU2013106427/04A patent/RU2013106427A/ru not_active Application Discontinuation
- 2011-07-15 CA CA2805608A patent/CA2805608A1/en not_active Abandoned
- 2011-07-15 KR KR1020137004056A patent/KR20130043198A/ko not_active Withdrawn
- 2011-07-15 NZ NZ607060A patent/NZ607060A/en not_active IP Right Cessation
- 2011-07-15 BR BR112013001088A patent/BR112013001088A2/pt not_active IP Right Cessation
- 2011-07-15 CN CN2011800448120A patent/CN103108873A/zh active Pending
- 2011-07-15 US US13/810,431 patent/US9062046B2/en not_active Expired - Fee Related
- 2011-07-15 EP EP11748466.7A patent/EP2593450A1/en not_active Withdrawn
- 2011-07-15 TW TW100125119A patent/TW201204725A/zh unknown
- 2011-07-15 AU AU2011277935A patent/AU2011277935B2/en not_active Ceased
- 2011-07-15 AR ARP110102555A patent/AR084706A1/es unknown
- 2011-07-15 WO PCT/IB2011/053161 patent/WO2012007926A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US9062046B2 (en) | 2015-06-23 |
| MX2013000617A (es) | 2013-06-13 |
| EP2593450A1 (en) | 2013-05-22 |
| KR20130043198A (ko) | 2013-04-29 |
| TW201204725A (en) | 2012-02-01 |
| CA2805608A1 (en) | 2012-01-19 |
| NZ607060A (en) | 2015-02-27 |
| US20130116248A1 (en) | 2013-05-09 |
| AU2011277935A1 (en) | 2013-03-07 |
| RU2013106427A (ru) | 2014-08-27 |
| BR112013001088A2 (pt) | 2016-05-24 |
| WO2012007926A1 (en) | 2012-01-19 |
| JP5750158B2 (ja) | 2015-07-15 |
| CN103108873A (zh) | 2013-05-15 |
| AU2011277935B2 (en) | 2015-01-22 |
| JP2013535446A (ja) | 2013-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR084706A1 (es) | Derivados sustituidos de imidazoquinolinas como inhibidores de quinasa y proceso para su preparacion | |
| MX390726B (es) | Procesos para preparar compuestos de quinolina y composiciones farmaceuticas que contienen tales compuestos. | |
| AR074021A1 (es) | Compuestos heterociclicos fusionados como moduladores del canal ionico | |
| MX361020B (es) | Procesos para preparar compuestos heterociclicos, incluida trans-7-oxo-6-(sulfooxi)-1,6-diazabiciclo [3,2,1]octano-2-carboxam ida y sales de la misma. | |
| CO7400872A2 (es) | Derivados sustituidos de ftalazin-1(2h)-ona | |
| AR083873A1 (es) | Derivados de acido amino-fenil-pentanoico sustituidos como inhibidores de nep | |
| PE20160540A1 (es) | Inhibidores de bromodominios | |
| AR085354A1 (es) | Derivados de isoxazol para control de pestes invertebrados | |
| AR081369A1 (es) | Compuestos de 2-5-6-7-tetrahidro-(1,4) oxazepin-3-ilamina o 2,3,6,7-tetrahidro-(1,4) oxazepin-5-ilamina, sus procesos de obtencion y composiciones farmaceuticas que los contienen | |
| CO7170131A2 (es) | Compuestos de heterociclilo | |
| EA201291414A1 (ru) | Имидазопиридиновые производные, способ их получения и терапевтическое использование | |
| ECSP11011365A (es) | Sales de adición de aminas que contienen grupos hidroxilo y/o carboxílicos con derivados de ácido aminonicotínico como inhibidores de dhodh | |
| EA201391158A1 (ru) | Диаминиевые соли фенотиазина и их применение | |
| MX2010001837A (es) | Derivados de 4-pirimidinasulfamida. | |
| AR085283A1 (es) | Antagonistas de hepcidina a base de sulfonaminoquinolina | |
| AR087915A1 (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1 | |
| ES2526902T3 (es) | Procesos de producción de inhibidores de la girasa y topoisomerasa IV | |
| AR091519A1 (es) | Inhibidores pirrolopirazona de tanquirasa | |
| AR092555A1 (es) | 2-oxo-2,3-dihidro-indoles y su utilizacion para el tratamiento de trastornos del snc | |
| AR082111A1 (es) | Furopiridinas o tienopiridinas condensadas, composiciones farmaceuticas que las contienen utiles para tratar trastornos psicoticos y del sistema nervioso central, y metodo de preparacion de las mismas | |
| AR098965A1 (es) | Derivados de sulfonamidas tricíclicas | |
| PL401473A1 (pl) | Nowe, silnie fluorescencyjne substancje heterocykliczne i sposób ich otrzymywania | |
| MA35188B1 (fr) | Tétrahydroquinolines à fusion cycloalkyle en tant que modulateurs de l'activité du récepteur crth2 | |
| BR112012030534A2 (pt) | moduladores de receptores 5-ht e métodos de uso dos mesmos | |
| EA201590069A1 (ru) | Пиримидиноновые производные в качестве антималярийных средств |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |